Filing search / Innovation Pharmaceuticals Inc. / "Environment"

Search information

Innovation Pharmaceuticals Inc.

Companies

"Environment"

Keywords

SEC filings

Source

Export list of results

Export a CSV file of filings or unique companies (up to first 5,000 results).

Download list of filings Download list of companies

48 results

Newest first Best match first

10-Q

2024 Q1

IPIX Innovation Pharmaceuticals Inc.

Quarterly report

investment that would not be prevented or detected on a timely basis. Management intends to enhance the Company’s internal control environment by refining

20 Nov 23

4:05pm

10-K

2023 FY

IPIX Innovation Pharmaceuticals Inc.

Annual report

in people. In Vitro: Refers to the technique of performing a given experiment in a test tube, or, generally, in a controlled environment outside … are in the areas of control environment, risk assessment, control activities, information and communication, and monitoring. The Company’s assessment

28 Sep 23

9:00am

10-K

2022 FY

IPIX Innovation Pharmaceuticals Inc.

Annual report

, in a controlled environment outside a living organism. NDA: A New Drug Application with the FDA. OM: Oral Mucositis. Oral mucositis is a common … ) in “Internal Control-Integrated Framework (2013).” These criteria are in the areas of control environment, risk assessment, control activities, information

28 Sep 22

4:00pm

10-Q

2022 Q2

IPIX Innovation Pharmaceuticals Inc.

Quarterly report

environment, we have prioritized development of Brilacidin for COVID-19, including the conduct of a Phase 2 randomized, blinded, placebo-controlled

14 Feb 22

4:00pm

10-Q

2022 Q1

IPIX Innovation Pharmaceuticals Inc.

Quarterly report

, alphaviruses and bunyaviruses. In light of the ongoing pandemic and drug development environment, we have prioritized development of Brilacidin for COVID

9 Nov 21

1:44pm

10-K

8kwlpg870p 4p

Annual report

27 Sep 21

4:16pm

424B5

wpxzki

10 Dec 20

Prospectus supplement for primary offering

Entry into a Material Definitive Agreement

14 Sep 20

4:50pm

424B5

ztylbk2b

4 Aug 20

Prospectus supplement for primary offering

Innovation Pharmaceuticals and U.S. Regional Biocontainment Laboratory Nearing Completion of Brilacidin Anti-SARS-CoV-2 (COVID-19) In Vitro Testing

Prospectus update (post-effective amendment)

30 Sep 19

4:37pm

POS AM

w504h7z5a

20 Sep 19

Prospectus update (post-effective amendment)

Prospectus supplement for primary offering

Innovation Pharmaceuticals Secures Up to $10 Million in Additional Financing to Advance Clinical Pipeline

Prospectus supplement for primary offering

11 Sep 18

12:00am

424B5

x9r4j14xart 2tceln

29 Jun 18

Prospectus supplement for primary offering

11 Sep 17

12:00am

Filing search / Innovation Pharmaceuticals Inc. / "Environment"

48 results

Top filers

Top filing types

Recent filing years